Xeris Biopharma Holdings (XERS) Change in Acquisitions & Divestments (2020 - 2024)

Xeris Biopharma Holdings' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $10.2 million for Q4 2024.

• Quarterly Change in Acquisitions & Divestments fell 31.76% year-over-year to $10.2 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $10.2 million (down 77.25% YoY) and the FY2024 annual result came in at $40.2 million, up 0.59% from the prior year.
• Change in Acquisitions & Divestments was $10.2 million for Q4 2024 at Xeris Biopharma Holdings, down from $15.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $34.6 million in Q1 2021 and bottomed at $5.0 million in Q1 2024.
• A 5-year average of $14.8 million and a median of $11.3 million in 2021 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments slumped 80.66% — and 2023, when it jumped 117.86%.
• Xeris Biopharma Holdings' Change in Acquisitions & Divestments stood at $17.8 million in 2020, then slumped by 41.14% to $10.5 million in 2021, then decreased by 11.43% to $9.3 million in 2022, then surged by 61.29% to $15.0 million in 2023, then slumped by 31.76% to $10.2 million in 2024.
• Business Quant data shows XERS's Change in Acquisitions & Divestments at $10.2 million in Q4 2024, $15.0 million in Q3 2024, and $10.0 million in Q2 2024.